Chimeric tumor suppressor-1 (CTS-1) is based on the sequence of p53 and was designed as a therapeutic tool resisting various mechanisms of p53 inactivation. We previously reported that an adenovirus expressing CTS-1 (Ad-CTS-1) has superior cell deathinducing activity in glioma cells compared with wild-type p53. Here, we used cDNA microarrays to detect changes in gene expression preferentially induced by Ad-CTS-1. The putative serin threonine kinase, PCTAIRE3, and the quinone oxireductase, PIG3, were strongly induced by Ad-CTS-1 compared with wild-type p53. An adenoviral vector encoding PCTAIRE3 (Ad-PCTAIRE3) induced growth arrest and killed a minor proportion of the glioma cells. Ad-PIG3 alone affected neither growth nor viability. However, coinfection with Ad-PCTAIRE3 and Ad-PIG3 resulted in enhanced growth inhibition compared with Ad-PCTAIRE3 infection alone. Ad-CTS1, Ad-PCTAIRE3 or Ad-PIG3 induced the formation of free reactive oxygen species (ROS). However, the prevention of ROS formation induced by Ad-PCTAIRE3 and Ad-CTS-1 did not block growth arrest and cell death, suggesting that ROS formation is not essential for these effects. Altogether, these data identify PCTAIRE3 as one novel growth-inhibitory and deathinducing p53 response gene and suggest that changes in the expression of specific target genes contribute to the superior antiglioma activity of CTS-1.
Introduction
The most common malignant brain tumor, glioblastoma, is rather resistant to current approaches of therapy. Standard therapy includes cytoreductive neurosurgery, radiotherapy and adjuvant chemotherapy and prolongs survival from about 3-4 months without such therapy to 12-15 months. 1, 2 Glioblastomas kill by local destructive growth, but hardly ever metastasize outside the central nervous system. Glioblastoma is, therefore, still a major target for novel strategies of somatic gene therapy.
The chimeric tumor suppressor-1, CTS-1, is a synthetic p53 analog, which has the aminoterminal domain of p53 substituted by the transactivator domain of the viral protein, VP16. An optimized leucine zipper at the carboxyterminus substitutes the p53 oligomerization domain. The carboxyterminal self-inhibitory domain of p53 is deleted.
3 Adenoviral CTS-1 gene transfer induces growth arrest and loss of viability in p53 wild-type and p53 mutant human malignant cell lines better than wildtype p53 4 as well as in mouse-double-minute-2 (MDM-2)-overexpressing breast cancer cells. 5 Since the best-established function of p53 is to act as a transcription factor regulating the expression of genes involved in growth inhibition, DNA repair and apoptosis, we here assessed whether specific differences in the modulation of gene expression are responsible for the superior antitumor properties of CTS-1 compared with wild-type p53 using cDNA microarray analysis.
Materials and methods
Cell lines and reagents U87MG, LN-18, LNT-229 and LN-308 are human malignant glioma cell lines, kindly provided by N de Tribolet (Lausanne, Switzerland). U87MG p53si and LNT-229 p53si cells were stably transfected with pSUPERpuro containing a p53-siRNA sequence under the control of the human H1-promoter. 6 Glioma cell lines expressing dominant-negative p53 V135A were prepared as described. 7 All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO Life Technologies, Eggenstein, Germany) containing 10% fetal calf serum (FCS), glutamine (2 mM), penicillin (100 IU/ml)/ streptomycin (100 mg/ml) and the appropriate antibiotics. Hoechst 33258, propididum iodide (PI), uric acid, catalase and tiron (disodium-4,5-dihxydroxybenzene-1,3-disulphonate) were obtained from Sigma (Deisenhofen, Germany), dichlorodihydro-fluorescin-diacetate (H 2 DCFDA) and dihydroethidium (DHE) were from Molecular Probes (Leiden, Netherlands), zVAD-fmk (benzyloxycarbonylVal-Ala-DL-Asp-fluoromethylketone) from Bachem (Weil am Rhein, Germany).
Construction of adenoviral vectors and infection procedure
The construction of Ad-CTS-1 encoding CTS-1, Ad-LacZ encoding b-galactosidase, Ad-EGFP encoding the enhanced green fluorescent protein and Ad-DE1, encoding no transgene, has been described. 4 Ad-p53-EGFP (Ad-p53) was a kind gift from B Vogelstein (Baltimore, MD). Ad-PCTAIRE3-EGFP (Ad-PCTAIRE3) and Ad-PIG3-EGFP (Ad-PIG3) were prepared by cloning cDNA into pTRACK-CMV using the Ad-Easy system provided by B Vogelstein (Baltimore, MD). Recombinant adenoviral genomes were transfected into human embryonic kidney 293 cells (ATCC #CRL-1573) by calcium phosphatemediated gene transfer. Virus preparations were purified by double cesium chloride gradient centrifugation. Transgene expression and the absence of adenoviral E1A sequence were verified by reverse transcriptase polymerase chain reaction (RT-PCR) and immunoblot. Viral titers were assessed by the plaque forming unit test (PFU) . 8 Infection with recombinant viruses was accomplished by exposing cells to different concentrations of adenovirus in serum-free DMEM for 15 min followed by the addition of serum-containing medium for 1-5 days.
RT-PCR Total RNA was extracted using an RNA purification system (RNeasy, Qiagen, Hilden, Germany) and treated with RNase-free DNase I to remove contamination of genomic DNA (Roche, Mannheim, Germany). Total RNA (5 mg) was used for the RT reaction using oligo (dT) 20 PCR primers and conditions as follows: human PCTAIRE3 forward TCCGAGAGGTGTCTCTGCTG (nucleotides 281-300), human PCTAIRE3 reverse ACACGAGCAGGCTGCTCAGG (nucleotides 940-920), yielding a 660 base pair product (35 cycles, T anneal ¼ 511C), GAPDH forward ACGACAGTCCATG CCATCAC (nucleotides 4209-4228) and GAPDH reverse TCCACCACCCTGTTCCTGTA (nucleotides 4761-4742), yielding a 552 base pair product (35 cycles, T anneal ¼ 50.51C). The PCR products were separated on agarose gels and stained with ethidium bromide.
Hybridization and quantification of cDNA arrays For cDNA microarray analysis, LN-18 cells were infected with the following viral combinations of 300 multiplicity of infection (MOI) for each virus: (i) Ad-DE1 þ Ad-EGFP, (ii) Ad-p53-EGFPþAd-DE1 and (iii) Ad-CTS-1 þ Ad-EGFP. These infection combinations allowed equal EGFP expression as well as equal PFU in all infections. At 48 h after infection, total RNA was isolated using the RNeasy kit (Qiagen, Hilden, Germany). To remove genomic DNA contamination, RNA was treated with RNase-free DNase I (Roche, Basel, Switzerland), dissolved in RNase-free H 2 O and stored at À801C until analysis. For cDNA probe synthesis, 5 mg DNase-treated total RNA and 1 ml primer mix (Clontech, Palo Alto, CA) in 6 ml were heated to 701C for 10 min and then cooled on ice. A mixture consisting of 4 ml 5 Â first-strand cDNA buffer (Life Technologies, Gaithersburg, MD), 1 ml 100 mM DTT, 2 ml 10 mM dNTP (Clontech), 1 ml RNase block (40 U/ml; Stratagene, La Jolla, CA) and 5 ml [a-32 P]dATP (3000 Ci/mmol, 10 mCi/ml; ICN, Eschwege, Germany) was added and heated at 421C for 2 min. Then, 1 ml (200 U) SuperScript II RNase H reverse transcriptase (Life Technologies) was added, and the reaction was continued at 421C for 50 min, followed by heating to 701C for 15 min for enzyme inactivation. The cDNA probe was purified with a CHROMA SPIN-200DEPC-H 2 O column (Clontech). Incorporation of 32 P into the probe was determined by counting in a liquid scintillation counter (BETAMATIC, Kontron Instruments, Montigny le Bretonneux, France). The first two fractions showing the highest counts were collected and used for hybridization with the cDNA array. 9 The Atlas Human Apoptosis (7743-1) Array and Atlas Human Cell Cycle Array (7748-1) were purchased from Clontech. Array membranes were prehybridized with 5 ml ExpressHyb solution (Clontech) at 681C with continuous rotation in a glass hybridization roller. After prehybridization for 2 h, purified 32 P-labeled cDNA was added into different rollers and hybridization was continued overnight at the same temperature. Arrays were subsequently washed twice in 200 ml of wash solution 1 (2 Â SSC, 1% SDS) at 681C for 20 min with agitation and then washed once in 200 ml wash solution 2 (0.1 Â SSC, 0.5% SDS) at 681C for 20 min with agitation. After a final wash with 200 ml 2 Â SSC for 5 min at room temperature, the membranes were sealed in plastic wrap and exposed to Kodak Biomax MS X-ray film with an intensifying screen at À801C for 6 days. 9 Array images on the X-ray film were scanned at 400 dpi using an image scanner (X-Finity professional, Model PS4800 þ ; PFU Limited, Ishikawa, Japan) and then analyzed using AtlasImage 2.01a software (Clontech) as described. 9 Cell cycle analysis and growth and viability assays For cell cycle analysis, subconfluent cells were infected at increasing MOI or time periods. Detached cells were harvested from the supernatant by centrifugation and added to the nondetached cells harvested by trypsinization. The cells were washed with PBS, fixed in 70% icecold ethanol, centrifuged, washed with PBS, and 10 5 cells per condition were stained with PI (50 mg/ml) diluted in PBS containing RNase A (100 mg/ml). The cells were subjected to flow cytometric analysis of DNA content using a Becton Dickinson FACSCalibur cytometer (Heidelberg, Germany).
Net cell culture growth was determined by crystal violet staining. Briefly, the cells were stained with crystal violet for 10 min followed by several washes with tap water. Bound crystal violet was dissolved in 50% ethanol/0.1 M sodium citrate and optical density readings were obtained using an ELISA reader (Thermo Electron Multiskan EX) at 560 nm. To assess viability, the cells were trypsinized and analyzed using the CASY system (Scha¨rfe Diagnostics, Reutlingen, Germany). This method assesses the viability of cells by cell size and measurement of the electric resistance in a capillary containing an electric field. 10 
Immunoblot analysis
The general procedure has been described. 4 The following antibodies were used: anti-VP16 (SC-7545, Santa Cruz Biotechnology, Santa Cruz, CA); anti-PIG3 (N-20, Santa Cruz SC-16325), anti-p53 (Bp53-12, Santa Cruz SC-263); anti-MDM2 (SMP15, Santa Cruz SC-965) and antib-actin (I-19, Santa Cruz SC-1616).
Detection of ROS
To assess ROS generation, the cells were washed with PBS, incubated with 5 mM H 2 -DCFDA in cell culture medium for 15 min at 371C, washed with PBS again, trypsinized and harvested by centrifugation. The pellets were resuspended in PBS, counterstained with PI to detect dead cells, and viable cells defined by PI exclusion were analyzed by flow cytometry in a Becton Dickinson FACScalibur cytometer using the CellQuest analysis program. EGFP-positive cells, which cannot be analyzed using the more robust green fluorescent chemical H 2 -DCFDA, were incubated with the red fluorescent radical detector DHE (5 mM, 15 min, 371C), counterstained with Hoechst 33258 to exclude dead cells and analyzed as above.
Electron microscopy
The cells were treated as indicated, fixed in 2.5% glutaraldehyde in Hank's modified salt solution, postfixed in 1% OsO 4 in 0.1 M cacodylate buffer, scraped off and dehydrated in a series of ethanol. The 70% ethanol step was saturated with uranyl acetate for contrast enhancement. Dehydration was completed in propylene oxide and the specimens were embedded in Araldite (Serva, Heidelberg, Germany). Ultrathin sections were produced on a FCR Reichert Ultracut ultramicrotome (Leica, Bensheim, Germany), mounted on pioloform-coated copper grids and contrasted with lead citrate. Specimens were analyzed and documented with an EM 10A electron microscope (Zeiss, Oberkochen, Germany).
Statistical analysis
The figures show representative data from three separate experiments with similar results. Data were assessed for significant differences using t-test (*Po0.05). Synergy was assessed by the fractional product method. 11 
Results

Transcriptional regulation of apoptosis-and cell cyclerelevant genes: comparison of CTS-1 and p53
The p53 mutant glioma cell line LN-18 was infected with Ad-CTS-1 þ Ad-EGFP, Ad-p53-EGFP þ Ad-DE1 or Ad-EGFP þ Ad-DE1 at a multiplicity of infection (MOI) of 300 for each virus for 48 h. These infections assure equal rates of infectious viral particles (PFU) during infection as well as equal protein expression in all viral combinations and allow to identify genes upregulated solely in response to adenoviral infection (Ad-EGFP, expressing the enhanced green fluorescent protein) and to assess whether changes in transcriptional regulation may contribute to the superior anti-glioma activity of CTS-1 compared with wild-type p53. 4 Changes in gene expression were assessed by cDNA array technology on ATLAS Human Apoptosis and Cell Cycle Arrays. Common p53 response genes like mdm-2 and Fas/CD95/Apo1, proliferating cyclic nuclear antigen (PCNA) or bax were upregulated by Ad-p53 and Ad-CTS-1, serving as positive controls in these experiments. Moreover, the expression of some other genes appeared to be preferentially or exclusively increased by Ad-CTS-1 (Table 1) . To verify the results of the array analysis, the altered expression of selected genes was reassessed by RT-PCR and immunoblot. Two genes of interest, apparently preferentially induced by Ad-CTS-1, were selected for further study: PIG3 (p53-inducible gene 3, Acc #AF010309), which was chosen because its expression is highly upregulated after Ad-CTS-1-infection, was originally isolated from a serial analysis of gene expression (SAGE) library 12 and encodes a quinone oxireductase. PCTAIRE3 (Acc #X66362) was chosen because its expression was solely induced by Ad-CTS-1 and not by Ad-p53. PCTAIRE3 encodes a putative p34 cdc2 -related serine threonine kinase involved in cell cycle regulation, based on sequence homology to the cell cycle-associated kinases, PCTAIRE1 and PCTAIRE2. 13 The latter two were included on the array, but not induced (data not shown). PCTAIRE3 is expressed at two isoforms in human brain 14 and had not been identified as a transcriptional target gene of p53 yet.
CTS-1 gene transfer induces PCTAIRE3 and PIG3 expression in human malignant glioma cells
The results obtained from the chip analysis were confirmed by infecting U87MG, LNT-229 and LN-18 glioma cells with Ad-EGFP, Ad-p53 or Ad-CTS-1. RT-PCR was used to determine changes in PCTAIRE3 expression since no antibody is available yet. There was a strong upregulation in response to Ad-CTS-1 in U87MG and LNT-229 and a week induction in LN-18 cells, but no induction of PCTAIRE3 transcription by Ad-p53 except for U87MG cells (Figure 1a ). PIG3 protein was strongly induced by Ad-CTS-1, but only weekly by Ad-p53 in U87MG and LNT-229 cells, whereas similar levels of PIG3 were induced by Ad-CTS1 and Ad-p53 in LN-18 cells (Figure 1b) . No induction of PCTAIRE3 or PIG3 expression was seen in Ad-EGFP-infected cells (Figure 1c) or Ad-DE1-infected cells (data not shown).
Biological effects of Ad-PCTAIRE3-EGFP and Ad-PIG3-EGFP gene transfer into human glioma cells
To determine the possible contribution of PCTAIRE3 and PIG3 to the overall effects of CTS-1 on glioma cells, we generated adenoviruses containing human PCTAIRE3 (Ad-PCTAIRE3) or PIG3 cDNA (Ad-PIG3) under the control of the human cytomegalovirus (CMV) promoter. In an independent transcriptional cassette, EGFP was expressed to monitor infection. As shown in Figure 2 , there was strong transgene expression at 24-48 h after infection with the appropriate virus. The infection rates assessed by counting EGFP-positive cells were 95% after infection at 100 MOI for 24 h (data not shown). To screen for antiproliferative or cell death-inducing activity of Ad-PCTAIRE3 or Ad-PIG3, LNT-229 glioma cells were infected with increasing MOI of virus and cell density was assessed. Figure 2c shows that Ad-PCTAIRE3 strongly reduced cell density at 96 h after viral infection, whereas no effects were detectable after Ad-PIG3 infection.
Since PCTAIRE3 encodes a putative serine threonine kinase involved in cell cycle regulation, we analyzed cell cycle distribution and viability of glioma cells after Ad-PCTAIRE-3 infection. The infection of LN-18 and LNT-229 glioma cells with Ad-PCTAIRE3 resulted in an increase in the sub-G1 (apoptotic) fraction at 72 h, confirming some cytotoxic activity of Ad-PCTAIRE3. Further, at 72 h after Ad-PCTAIRE3 infection, the fraction of G0/1 phase cells decreased whereas the percentages of S and G2/M phase cells increased (Figure 3a) . Similar results were obtained in LN-18 cells (data nor shown). PIG3 overexpression did not modulate the cell cycle distribution in LN-18 or LNT-229 cells at any time up to 96 h or dose up to 300 MOI (data not shown). Relative to the strong reduction in cell density shown in Figure 2c , the induction of cell death summarized in Figure 3a appeared to be moderate, suggesting that PCTAIRE3 acts both to inhibit proliferation and to induce cell death. A time course of crystal violet assays confirmed a loss of cell density of up to 30% at 72 h relative to the initial cell density at the time point of viral infection (Figure 3b) . Moreover, the CASY viability assay confirmed that the actual cytotoxic effects of Ad-PCTAIRE3 are moderate even at 72 h (Figure 3c ), reflecting the data obtained by flow cytometry (Figure 3a , right panel). Taken together, these data identified both growth inhibition and induction of cell death as the effects of PCTAIRE3 in glioma cells. To ensure that the PCTAIRE3 effect was not limited to LNT-229 cells, we also infected p53 wild-type U87MG and p53 mutant LN-18 glioma cells with PCTAIRE3 alone or in combination with Ad-PIG3. As a positive control, the cells were infected with Ad-CTS-1 plus Ad-EGFP. Ad-PIG3 was devoid of antiproliferative or cytotoxic effects in either p53 wild-type LNT-229 or U87MG or p53 mutant LN-18 cells. In contrast, Ad-PCTAIRE3 inhibited growth in all cell lines, albeit to a different degree (Figure 3d) . Moreover, although PIG3 had no effect when expressed alone, PIG3 strongly enhanced the growth inhibitory effects of Ad-PCTAIRE in LNT-229 (Po0.01), but only moderately in U87MG and LN-18 cells (Po0.05) (Figure 3d ). We also assessed a possible modulation of PCTAIRE3-mediated growth inhibition and cell death by the endogenous p53 status. p53 was dispensable for PCTAIRE3-induced effects since LN-308 (p53 deleted) cells were no more resistant to Ad-PCTAIRE3 than LNT-229 cells (data not shown) and since LN-18 cells (p53 mutant) were sensitive, too (Figure 3d ). Moreover, LNT-229 or U87MG cells stably depleted from endogenous wild-type p53 by RNA interference 15 showed an unaltered sensitivity to Ad-PCTAIRE3 (Figure 4 ). Similar data were obtained when p53 function in LNT-229 cells was disabled by dominant-negative p53 V135A 7 (data not shown). The latter experiments also showed that very high levels of mutant p53 do not interfere with the effects of PCTAIRE3.
Morphological features of PCTAIRE-induced cell death: comparison with Ad-CTS-1
Electron microscopic analyses were performed to assess the morphological changes in the minority of cells which died in response to Ad-PCTAIRE3 infection. Some LNT-229 cells infected with Ad-PCTAIRE3 alone or in combination with Ad-PIG3 showed nuclear fragmentation and chromatin condensation (Figure 5e-h) , whereas the majority of cells showed no or only minor morphological changes. No morphological alterations were detected in control-infected cells or in cells infected with Ad-PIG3 alone (Figure 5a-d) . The flattened morphology of many cells was lost at 24 h after the treatment with Ad-PCTAIRE3 plus Ad-PIG3. The nucleus was swollen and cellular organelles such as ribosomes and cisterns of the endoplasmic reticulum or of the Golgi apparatus were enriched (Figure 5g, h) . A wide variability of structural changes in LNT-229 cells was detectable, ranging from nearly unaltered cells to necrotic cell debris at 72 h after infection. Overall, cell death had features of necrotic and necraptotic death. 16 In contrast to the changes seen in PIG3/PCTAIRE3-infected cells, CTS-1-induced cell death more closely resembled classical apoptosis. Membrane blebbing as well as chromatin condensation evolved Potential mediators of CTS-1-induced cell death U Naumann et al at 24 h after infection (Figure 5i ). Many cells rounded and lost their cell-cell contacts and flattened character. At 72 h after Ad-CTS infection, nearly all cell structures were lost, few apoptotic cells and massive cell debris as well as final stages of apoptosis and secondary necrosis were also found ( Figure 5j ). 4 Modulation of glioma cell viability by CTS-1, PCTAIRE3 or PIG3: the role of ROS formation PIG3 is a quinone oxireductase thought to be involved in the production of ROS. [17] [18] [19] We therefore tested whether adenoviral CTS-1, PIG3 or PCTAIRE3 gene transfer induced ROS formation in human glioma cells. Either Ad-CTS-1, Ad-PIG3 or Ad-PCTAIRE3 induced ROS formation within 48 h (Figure 6a ). The coinfection with Ad-PIG3 and Ad-PCTAIRE3 had additive effects determined by the fractional product method. 11 To gain insight into the type of ROS generated, LN-18 and LNT-229 cells were infected with Ad-CTS-1 or Ad-DE1 in the absence or presence of specific antioxidants. Coexposure to uric acid, a natural scavenger of peroxynitrite, led to a reduction in ROS levels after Ad-CTS-1 infection. In contrast, tiron (superoxide radicals) or catalase (hydrogen peroxide) had no such effect (Figure 6b, upper panel) . Yet, neither uric acid nor tiron nor catalase protected glioma cells from Ad-CTS-1-induced growth inhibition and cell death (Figure 6b, lower panel) . ROS levels induced by Ad-PCTAIRE3 were decreased by uric acid or tiron, whereas PIG3-induced ROS formation was unaffected (Figure 6c, upper panel) . Similar to CTS-1, neither uric 
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∆ E + E G F P ∆ E + P C T A I R E 3 ∆ E + P I G 3 ∆ E + P I G 3 ∆ E + P I G 3 Potential mediators of CTS-1-induced cell death U Naumann et al acid nor tiron nor catalase modulated the PCTAIRE3-induced decrease in cell density (Figure 6c, lower panel) . Importantly, no such ROS generation was observed when the cells were killed with CD95L or Triton X-100 (data not shown), confirming that ROS generation is not an unspecific general feature of glioma cell death.
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Discussion
CTS-1 is a synthetic p53-based gene designed to overcome some of the mechanisms that interfere with the efficacy of p53 gene therapy in human cancer. 3 We previously reported that Ad-CTS-1 kills human gliomas independent of their endogenous p53 status and more efficiently than wild-type p53. The biochemical pathways mediating CTS-1-induced cell death remained obscure, but did not involve death ligand/receptor interactions, caspase activation or altered BCL-2 family protein expression. 4 Since CTS-1 supposedly acts as a transcription factor unable to induce cell death per se, we reasoned that CTS-1 induces either specific changes in gene expression distinct from p53 or merely the same changes as p53, but in a more efficient manner. Using cDNA microarray technology, we detected a variety of genes induced by p53 and CTS-1 as well as many genes induced much stronger by CTS-1 than p53 (Table 1 , data not shown). The cDNA array findings as well as confirmatory mRNA and protein studies of several known p53 response genes ( Figure 1 ) demonstrated that stronger transcriptional activation of p53 response genes is one possible mechanism explaining the superior activity of CTS-1 compared with wild-type p53. CTS-1, in contrast to p53, contains a very potent VP-16 transactivator domain and may therefore strongly induce p53-responsive genes that are only moderately or even not measurably induced by p53. Further, CTS-1 upregulates MDM-2 and therefore enhances the ubiquitin-dependent degradation of p53 4 and presumably of some isoforms of the p53 relatives, p63 and p73. [20] [21] [22] Thus, the stronger transcriptional activity of CTS-1 might not be the sole cause of the more potent induction of cell death. Rather, the MDM-2-induced degradation of p53 and its relatives might alter protein-protein interactions involving p53, Potential mediators of CTS-1-induced cell death U Naumann et al p63 or p73 isoforms and other, yet unknown effectors of cell death and thereby contribute to the cell death induction in response to Ad-CTS1. Here, we focused on two genes strongly induced by CTS-1, PCTAIRE3 and PIG3, as confirmed by RT-PCR or immunoblot (Figure 1 ). PCTAIRE3 is a putative member of the cdc2/cdk1-related protein kinase gene family. 13, 23 Two isoforms, PCTAIRE-3a and -3b, are expressed in the brain.
14 Putative binding sites for the central nervous system transcription factors GATAbinding protein-2 (GATA2), sex-determining-region-Y (SRY) and nuclear factor-E2 p45-related factor-2 (NRF-2) were found in the PCTAIRE3 promotor region. PCTAIRE3 has not been identified as a p53-inducible gene previously.
14 PIG3 encodes a quinone oxireductase 24 possibly involved in an oxidative stress-mediated cell death pathway. 19 To assess whether PCTAIRE3 or PIG3 may mediate p53-or CTS-1-induced cell death, we generated adenoviruses encoding these genes. The expression of the transgenes as assessed by RT-PCR or immunoblot was confirmed to be dose (MOI)-and time-dependent (Figure 2a, b and data not shown) . Glioma cell growth was strongly inhibited by Ad-PCTAIRE3, but not by Ad-PIG3 (Figure 2c ). To distinguish antiproliferative and cytotoxic effects of PCTAIRE3, we performed flow cytometric analyses determining DNA content. These data indicated that cytotoxic effects account only for a part of the growth inhibition mediated by Ad-PCTAIRE3 (Figure 3a) . This induction of cell death was confirmed by viablity assays using the CASY technology (Figure 3c) . Moreover, PCTAIRE3, a putative cell cycle kinase, in addition to inducing some cell loss by cytotoxicity, increased the proportion of S and G2/M phase cells whereas G0/1 cells decreased. We conclude that PCTAIRE3 is an inhibitor of glioma cell proliferation that appears to act in a cell cycle-selective manner and exhibits cytotoxic properties, too. The antiproliferative and cytotoxic effects of Ad-PCTAIRE3 were not only seen in the p53 wild-type cell line, LNT-229, but also in another p53 wild-type cell line, U87MG, as well as in two cell lines lacking functional p53, LN-18 and LN-308 (Figure 3d and data not shown). Moreover, stably disrupting endogenous p53 function by RNA interference (Figure 4 ) or dominantnegative p53 (data not shown) did not affect the effects induced by PCTAIRE3 alone or in concert with PIG3 ( Figure 4 and data not shown). Although Ad-PIG3 induced neither growth inhibition nor cytotoxicity in any of the assays used here, coinfection of all cell lines with Ad-PCTAIRE3 and Ad-PIG3 enhanced the effects relative to Ad-PCTAIRE3 alone (Figure 3d) .
The morphological features of PCTAIRE3-induced cell death were distinct from those induced by CTS-1 in that the hallmarks of apoptosis were less prominent with PCTAIRE3 ( Figure 5 ). Thus, PCTAIRE3 may be just one mediator of CTS-1-induced growth inhibition and cell death in glioma cells. Although growth inhibition and cell death induced by CTS-1, PCTAIRE3 or PCTAIRE3 plus PIG3 were paralleled by the generation of ROS, appropriate control experiments using various antioxidants disclosed no role for ROS in mediating growth arrest or cell death ( Figure 6 ).
In summary, these observations are consistent with the idea that PCTAIRE3 and PIG3 contribute to growth inhibition and cell death mediated by CTS-1, but are Potential mediators of CTS-1-induced cell death U Naumann et al
probably not the only players in that process. We identify PCTAIRE3 as a novel p53-responsive gene with dual function. It induces cell cycle arrest as well as cell death. Our data suggest that changes in the expression of specific target genes contribute to the superior anti-glioma activity of CTS-1.
